Autopsy report · NCT07361094

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“No participants.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 1
Sponsor: Beijing Boren Hospital
Sponsor type: University, hospital or other
Conditions: Relapsed/Refractory Systemic Lupus Erythematosus; Relapsed/Refractory Systemic Sclerosis; Relapsed/Refractory Idiopathic Inflammatory Myopathies; Relapsed/Refractory sjögren's Syndrome; Relapsed/Refractory Autoimmune Hemolytic Anemia; Relapsed/Refractory Multiple Sclerosis
Interventions: Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy
Participants: 0
Sites: 1
Countries: China

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.